var data={"title":"Potassium phosphate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Potassium phosphate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6818?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=potassium-phosphate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Potassium phosphate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=potassium-phosphate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Potassium phosphate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50409434\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>K-Phos</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212083\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Electrolyte Supplement, Parenteral;</li>\n      <li>\n        Urinary Acidifying Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212070\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute treatment of hypophosphatemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> If phosphate repletion is required and a phosphate product is not available at your institution, consider the use of sodium glycerophosphate pentahydrate (Glycophos) as a suitable substitute. Concentration and dosing are different from FDA-approved products; use caution when switching between products. Refer to Sodium Glycerophosphate Pentahydrate monograph.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Caution: The concomitant amount of potassium must be calculated into the total electrolyte content. For each 1 mmol of phosphate, ~1.5 mEq of potassium will be administered. Therefore, if ordering 30 mmol of potassium phosphate, the patient will receive ~45 mEq of potassium. With orders for IV phosphate, there is considerable confusion associated with the use of millimoles (mmol) versus milliequivalents (mEq) to express the phosphate requirement.</b> The most reliable method of ordering IV phosphate is by millimoles, then specifying the potassium or sodium salt. Doses listed as mmol of phosphate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Repletion of severe hypophosphatemia should be done IV because large doses of oral phosphate may cause diarrhea and intestinal absorption may be unreliable. Reserve intermittent IV infusion for severe depletion situations; may require continuous cardiac monitoring depending on potassium administration rate. Guidelines differ based on degree of illness, need/use of parenteral nutrition, and severity of hypophosphatemia. If potassium &gt;4.0 mEq/L consider phosphate replacement strategy without potassium (eg, sodium phosphates). Patients with severe renal impairment were excluded from phosphate supplement trials. <b>Note:</b> 1 mmol phosphate = 31 mg phosphorus; 1 mg phosphorus = 0.032 mmol phosphate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General replacement guidelines</b> (Lentz 1978): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low dose, if serum phosphate losses are recent and uncomplicated: Initial: 0.08 mmol/kg over 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermediate dose, if serum phosphorus level &lt;1 mg/dL (&lt;0.32 mmol/L): Initial: 0.16 mmol/kg per dose over 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> The initial dose may be increased by 25% to 50% if the patient is symptomatic secondary to hypophosphatemia and lowered by 25% to 50% if the patient is hypercalcemic. Do not exceed the maximum dose of 0.24 mmol/kg/dose (or 16.9 mmol for a 70-kg patient).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Critically-ill adult patients receiving concurrent enteral/parenteral nutrition (Brown 2006; Clark 1995):</b> IV: <b>Note:</b> Round doses to the nearest 7.5 mmol for ease of preparation. If administering with phosphate-containing parenteral nutrition, do not exceed 15 mmol/L within parenteral nutrition.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low dose, serum phosphorus level 2.3 to 3 mg/dL (0.74 to 0.96 mmol/L): 0.16 to 0.32 mmol/kg over 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermediate dose, serum phosphorus level 1.6 to 2.2 mg/dL (0.51 to 0.71 mmol/L): 0.32 to 0.64 mmol/kg over 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High dose, serum phosphorus &lt;1.5 mg/dL (&lt;0.5 mmol/L): 0.64 to 1 mmol/kg over 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Obesity: May use adjusted body weight for patients weighing &gt;130% of ideal body weight (and BMI&lt;40 kg/m<sup>2</sup>) by using [IBW + 0.25 (actual body weight - IBW)].</p>\n    <p style=\"text-indent:-4em;margin-left:4em;margin-top:2em;\">\n      <b>Parenteral nutrition:</b> IV: 10 to 15 mmol/1,000 kcal (Hicks, 2001) <b>or</b> 20 to 40 mmol/24 hours (Mirtallo 2004 [ASPEN guidelines])</p>\n    <p style=\"text-indent:-4em;margin-left:4em;margin-top:2em;\">\n      <b>Urine acidification: </b>Oral: 1,000 mg 4 times daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212078\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=potassium-phosphate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Potassium phosphate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute treatment of hypophosphatemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> If phosphate repletion is required and a phosphate product is not available at your institution, consider the use of sodium glycerophosphate pentahydrate (Glycophos) as a suitable substitute. Concentration and dosing are different from FDA-approved products; use caution when switching between products. Refer to Sodium Glycerophosphate Pentahydrate monograph.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Caution: The concomitant amount of potassium must be calculated into the total electrolyte content. For each 1 mmol of phosphate, ~1.5 mEq of potassium will be administered. Therefore, if ordering 30 mmol of potassium phosphate, the patient will receive ~45 mEq of potassium. With orders for IV phosphate, there is considerable confusion associated with the use of millimoles (mmol) versus milliequivalents (mEq) to express the phosphate requirement.</b> The most reliable method of ordering IV phosphate is by millimoles, then specifying the potassium or sodium salt. Doses listed as mmol of phosphate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV infusion should be reserved for severe depletion situations; may require continuous cardiac monitoring depending on potassium administration rate. It is difficult to determine total body phosphorus deficit. There are no prospective studies of parenteral phosphate replacement in children. The following weight-based guidelines for <b>adult</b> dosing may be cautiously employed in pediatric patients. Guidelines differ based on degree of illness, use of TPN, and severity of hypophosphatemia. <b>Note:</b> 1 mmol phosphate = 31 mg phosphorus; 1 mg phosphorus = 0.032 mmol phosphate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General replacement guidelines (Lentz 1978):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low dose, if serum phosphate losses are recent and uncomplicated: Initial: 0.08 mmol/kg over 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermediate dose, if serum phosphorus level &lt;1 mg/dL (&lt;0.32 mmol/L): Initial: 0.16 mmol/kg per dose over 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> The initial dose may be increased by 25% to 50% if the patient is symptomatic secondary to hypophosphatemia and lowered by 25% to 50% if the patient is hypercalcemic. Do not exceed the maximum dose of 0.24 mmol/kg/dose (or 16.9 mmol for a 70-kg patient).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Critically-ill adult patients receiving concurrent enteral/parenteral nutrition (Brown 2006; Clark 1995):</b> IV: <b>Note:</b> Round doses to the nearest 7.5 mmol for ease of preparation. If administering with phosphate-containing parenteral nutrition, do not exceed 15 mmol/L within parenteral nutrition.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low dose, serum phosphorus level 2.3 to 3 mg/dL (0.74 to 0.96 mmol/L): 0.16 to 0.32 mmol/kg over 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermediate dose, serum phosphorus level 1.6 to 2.2 mg/dL (0.51 to 0.71 mmol/L): 0.32 to 0.64 mmol/kg over 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High dose, serum phosphorus &lt;1.5 mg/dL (&lt;0.5 mmol/L): 0.64 to 1 mmol/kg over 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Obesity: May use adjusted body weight for patients weighing &gt;130% of ideal body weight (and BMI&lt;40 kg/m<sup>2</sup>) by using [IBW + 0.25 (actual body weight - IBW)].</p>\n    <p style=\"text-indent:-4em;margin-left:4em;margin-top:2em;\">\n      <b>Parenteral nutrition:</b> IV:</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">Infants and Children: 0.5 to 2 mmol/kg/24 hours (Mirtallo 2004 [ASPEN guidelines])</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">Children &gt;50 kg and Adolescents: 10 to 40 mmol/24 hours (Mirtallo 2004 [ASPEN guidelines])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212071\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50409437\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Contraindicated in patients with severe impairment (&lt;30% of normal function) or with hyperphosphatemia or hyperkalemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50409438\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20330582\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to indication-specific dosing for obesity-related information (may not be available for all indications).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212056\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution: Potassium 4.4 mEq and phosphorus 3 mmol per mL (5 mL, 15 mL, 50 mL) [equivalent to potassium 170 mg and elemental phosphorus 93 mg per mL]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">K-Phos: 500 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212041\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Injection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963625\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium 4.4 mEq is equivalent to potassium 170 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorous 3 mmol is equivalent to phosphorus 93 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Each mmol of phosphate contains 31 mg elemental phosphorus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212058\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Injection must be diluted in appropriate IV solution and volume prior to administration. In general, the dose, concentration of infusion, and rate of administration may be dependent on patient condition and specific institution policy. Must consider administration precautions for phosphate and potassium when prescribing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">For adult patients with severe symptomatic hypophosphatemia (ie, &lt;1.5 mg/dL), may administer at rates up to 15 mmol phosphate/hour (this rate will deliver potassium at 22.5 mEq/hour) (Charron 2003; Rosen 1995). Potassium infusion rates &gt;10 mEq/hour should be administered via central line (minimizes burning and phlebitis). ECG monitoring is recommended for potassium infusions &gt;10 mEq/hour in adults or &gt;0.5 mEq/kg/hour in children. In patients with renal dysfunction and/or less severe hypophosphatemia, slower administration rates (eg, over 4 to 6 hours) or oral repletion is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vesicant/irritant (may depend on concentration); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry cold compresses (Hurst 2004); elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Zenk 1981).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Oral: Administer at mealtime and at bedtime. Dissolve tablets in 6 to 8 oz of water prior to administration to avoid GI injury. For best results, soak tablets in water for at least 2 to 5 minutes and stir. If any tablet particles remain undissolved, crush and stir vigorously to speed dissolution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212057\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Treatment and prevention of hypophosphatemia; <b>Note:</b> The concomitant amount of potassium must be calculated into the total electrolyte content. For each 1 mmol of phosphate, ~1.5 mEq of potassium will be administered. Therefore, if ordering 30 mmol of potassium phosphate, the patient will receive ~45 mEq of potassium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: To acidify the urine to lower urinary calcium concentrations; reduce odor and rash caused by ammonia in urine; to increase the antibacterial activity of methenamine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212091\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Neutra-Phos-K [DSC] may be confused with K-Phos Neutral </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Per JCAHO recommendations, concentrated electrolyte solutions should not be available in patient care areas. </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Consider special storage requirements for intravenous potassium salts; IV potassium salts have been administered IVP in error, leading to fatal outcomes.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Safe Prescribing: Because inorganic phosphate exists as monobasic and dibasic anions, with the mixture of valences dependent on pH, ordering by mEq amounts is unreliable and may lead to large dosing errors. In addition, IV phosphate is available in the sodium and potassium salt; therefore, the content of these cations must be considered when ordering phosphate. The most reliable method of ordering IV phosphate is by millimoles, then specifying the potassium or sodium salt. For example, an order for 15 mmol of phosphate as potassium phosphate in one liter of normal saline.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212047\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac arrhythmia, chest pain, ECG changes, edema, heart block, hypotension, localized phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Confusion, lethargy, paralysis, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperkalemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, stomach pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Decreased urine output</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tetany (with large doses of phosphate), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212060\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Hyperphosphatemia, hyperkalemia, hypocalcemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Severe renal impairment (&lt;30% of normal function); hyperkalemia, hyperphosphatemia; infected phosphate stones</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212044\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant/irritant (may depend on concentration); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laxative effect: A mild laxative effect may occur with oral use within the first few days of therapy; if the laxative effect persists to a self-limiting degree, consider reducing the dose or discontinue use until diarrhea improves.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acid/base disorders: Use with caution in patients with acid/base alterations; changes in serum potassium concentrations can occur during acid/base correction, monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency (eg, Addison disease); adrenal insufficiency requires close monitoring of serum potassium and phosphorus concentrations to avoid hyperkalemia and/or hyperphosphatemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dehydration: Use with caution in patients with acute dehydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myotonia congenita: Use with caution in patients with myotonia congenita.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Use with caution in patients with acute pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parathyroid disease: Use with caution in patients with hypoparathyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal calculi: Patients with renal calculi may pass preformed stones when phosphate therapy is initiated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; renal impairment requires close monitoring of serum potassium and phosphorus concentrations to avoid hyperkalemia and/or hyperphosphatemia. Oral tablets are contraindicated in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rickets: Use with caution in patients with rickets; may increase the risk of extraskeletal calcification.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tissue breakdown: Use with caution in patients with extensive tissue breakdown (eg, severe burns).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral administration: Tablets should be dissolved completely in water prior to administration to avoid GI injury due to administration of a concentrated potassium salt preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parenteral administration: Use extreme caution when administering potassium phosphate parenterally; evaluate patient's renal function, cardiac and fluid status, and any factors contributing to altered potassium concentrations (eg, acidosis, alkalosis) prior to therapy. Closely monitor potassium and phosphate concentrations and response to therapy. Parenteral potassium may cause pain and phlebitis, requiring a decrease in infusion rate or potassium concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Calcium/phosphate compatibility: Admixture of phosphate and calcium in IV fluids can result in calcium phosphate precipitation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299925\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212049\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9799&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): Urinary Acidifying Agents may decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Urinary Acidifying Agents may decrease the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Urinary Acidifying Agents may decrease the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Potassium Phosphate. Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ChlorproPAMIDE: Urinary Acidifying Agents may increase the serum concentration of ChlorproPAMIDE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the absorption of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral iron salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Urinary Acidifying Agents may decrease the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an iron-containing oral multivitamin as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Potassium Phosphate may increase the serum concentration of Salicylates. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate administration. Administering oral phosphate supplements at least 1 hour before or 2 hours after administration of sucralfate may reduce the significance of the interaction.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212065\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid administering with oxalate (berries, nuts, chocolate, beans, celery, tomato) or phytate-containing foods (bran, whole wheat).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212052\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7828643\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Phosphorus requirements are the same in pregnant and nonpregnant women (IOM 1997). Although this product is not used for potassium supplementation, adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, preeclampsia; may be more likely to develop hyperkalemia) (IOM 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7828644\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Potassium is excreted into breast milk (IOM 2004). Phosphorus, sodium, and potassium are normal constituents of human milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212054\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Serum potassium, calcium, phosphorus, magnesium (to facilitate potassium repletion); cardiac monitor (if intermittent infusion or potassium infusion rates &gt;0.5 mEq/kg/hour in children or &gt;10 mEq/hour in adults); to assess adequate replacement, repeat serum potassium and phosphorus levels 2 to 4 hours after dose; renal function</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Serum potassium, phosphorus, and calcium; renal function; serum salicylate concentration (in patients taking concomitant salicylates)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13203038\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Reference ranges may vary depending on the laboratory</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium: 8.4 to 10.2 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum phosphorus: Both low and high ends of the normal range are higher in children than in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 4.5 to 7.5 mg/dL (1.45 to 2.42 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: ~4 to 6 mg/dL (1.29 to 1.94 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum potassium: 3.5 to 5.2 mEq/L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinary pH: 4.6 to 8</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21800538\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Phosphorus in the form of organic and inorganic phosphate has a variety of important biochemical functions in the body and is involved in many significant metabolic and enzymatic reactions in almost all organs and tissues. It exerts a modifying influence on the steady state of calcium levels, a buffering effect on acid-base equilibrium and a primary role in the renal excretion of hydrogen ion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Potassium is the major cation of intracellular fluid and is essential for the conduction of nerve impulses in heart, brain, and skeletal muscle; contraction of cardiac, skeletal and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism, and gastric secretion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46193189\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Well absorbed from upper GI tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Enters cells via active transport from extracellular fluid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily urine (&gt;80% to 90% of dose reabsorbed by the kidney); skin and feces (small amounts)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323717\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Potassium Phosphates Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mmole/5ml (5 mL): $17.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mmole/15ml (15 mL): $17.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mmole/50ml (50 mL): $80.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Potassium Phosphates-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15MMOL/250ML (250 mL): $21.77</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (K-Phos Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $55.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR &sect;201.323.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown KA, Dickerson RN, Morgan LM, et al, &ldquo;A New Graduated Dosing Regimen for Phosphorus Replacement in Patients Receiving Nutrition Support,&rdquo; <i>JPEN J Parenter Enteral Nutr</i>, 2006, 30(3):209-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-drug-information/abstract-text/16639067/pubmed\" target=\"_blank\" id=\"16639067\">16639067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Charron T, Bernard F, Skrobik Y, et al, &ldquo;Intravenous Phosphate in the Intensive Care Unit: More Aggressive Repletion Regimens for Moderate and Severe Hypophosphatemia,&rdquo; <i>Intensive Care Med</i>, 2003, 29(8):1273-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-drug-information/abstract-text/12845429/pubmed\" target=\"_blank\" id=\"12845429\">12845429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark CL, Sacks GS, Dickerson RN, et al, &ldquo;Treatment of Hypophosphatemia in Patients Receiving Specialized Nutrition Support Using a Graduated Dosing Scheme: Results from a Prospective Clinical Trial,&rdquo; <i>Crit Care Med</i>, 1995, 23(9):1504-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-drug-information/abstract-text/7664552/pubmed\" target=\"_blank\" id=\"7664552\">7664552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hicks W and Hardy G, &ldquo;Phosphate Supplementation for Hypophosphatemia and Parenteral Nutrition,&rdquo; <i>Curr Opin Clin Nutr Metab Care</i>, 2001, 4(3):227-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-drug-information/abstract-text/11517357/pubmed\" target=\"_blank\" id=\"11517357\">11517357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride</i>, National Academy of Sciences, Washington, DC, 1997.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate</i>, Washington, DC: National Academy Press, 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joint Commission on Accreditation of Healthcare Organizations, &ldquo;2005 National Patient Safety Goals.&rdquo; Available at http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/05_npsgs.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lentz RD, Brown DM, and Kjellstrand CM, &ldquo;Treatment of Severe Hypophosphatemia,&rdquo; <i>Ann Intern Med</i>, 1978, 89(6):941-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-drug-information/abstract-text/102230/pubmed\" target=\"_blank\" id=\"102230\">102230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo J, Canada T, Johnson D, et al, &ldquo;Safe Practices for Parenteral Nutrition,&rdquo; <i>JPEN J Parenter Enteral Nutr</i>, 2004, 28(6):S39-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-drug-information/abstract-text/15568296/pubmed\" target=\"_blank\" id=\"15568296\">15568296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perreault MM, Ostrop NJ, and Tierney MG, &ldquo;Efficacy and Safety of Intravenous Phosphate Replacement in Critically Ill Patients,&rdquo; <i>Ann Pharmacother</i>, 1997, 31(6):683-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-drug-information/abstract-text/9184705/pubmed\" target=\"_blank\" id=\"9184705\">9184705</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosen GH, Boullata JI, O'Rangers EA, et al, &ldquo;Intravenous Phosphate Repletion Regimen for Critically Ill Patients With Moderate Hypophosphatemia,&rdquo; <i>Crit Care Med</i>, 1995, 23(7):1204-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-drug-information/abstract-text/7600828/pubmed\" target=\"_blank\" id=\"7600828\">7600828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vannatta JB, Whang R, and Papper S, &ldquo;Efficacy of Intravenous Phosphorus Therapy in the Severely Hypophosphatemic Patient,&rdquo; <i>Arch Intern Med</i>, 1981, 141(7):885-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-drug-information/abstract-text/7235807/pubmed\" target=\"_blank\" id=\"7235807\">7235807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>.1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9799 Version 113.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50409434\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F212083\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F212070\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F212078\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F212071\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F50409437\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50409438\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20330582\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F212056\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F212041\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963625\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F212058\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F212057\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F212091\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F212047\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F212060\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F212044\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299925\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F212049\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F212065\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F212052\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7828643\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F7828644\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F212054\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F13203038\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F21800538\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F46193189\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323717\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9799|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=potassium-phosphate-patient-drug-information\" class=\"drug drug_patient\">Potassium phosphate: Patient drug information</a></li><li><a href=\"topic.htm?path=potassium-phosphate-pediatric-drug-information\" class=\"drug drug_pediatric\">Potassium phosphate: Pediatric drug information</a></li></ul></div></div>","javascript":null}